IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No. 5267

Joel Bernstein

Group Art Unit: 1614

Application No. 10/813,760

Examiner: Kwon, Brian Yong S.

Filed: March 31, 2004

For: COMPOSITIONS WITH REDUCED HEPATOTOXICITY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date
of a national application other than a continued prosecution application under
37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set
forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a
first Office Action on the merits; or (d) before the mailing of a first Office Action after
the filing of a request for continued examination under 37 CFR 1.114.

after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:

In re Application of Joel Bernstein Application No. 10/813,760

	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.
Copie	s of the References
\boxtimes	Copies of all non-patent literature and foreign patent references listed on the enclosed Form 1449 are enclosed herewith.
	Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3).
	Copy of Supplemental European Search Report is enclosed herewith.
Staten	nent under 37 CFR 1.97(e)
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

In re Application of Joel Bernstein Application No. 10/813,760

Fees	
\boxtimes	No fee is owed by the applicant(s).
	The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.
Meth	od of Payment of Fees
	Charge Deposit Account No. 12-0913 in the amount of \$180.00.
Auth	orization to Charge Additional Fees
\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-0913.
	Respectfully submitted,
	Affice O. Martin, Reg. No. 35,601 BARNES & THORNBURG LLP P.O. Box 2786 Chicago, Illinois 60690-2786 (312) 214-8316 (telephone) (312) 759-5646 (facsimile)
Date:	June 22, 2009
WEB	CERTIFICATION UNDER 37 CFR 1.8 I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with locuments referred to as being attached or enclosed) is being electronically filed via EFS addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on ate shown below.
Date:	June 22, 2009 S. Mitchell Donaldson